Transient Erythroblastopenia of Childhood
To view the entire topic, please log in or purchase a subscription.
5-Minute Clinical Consult (5MCC) app and website powered by Unbound Medicine helps you diagnose and manage 900+ medical conditions. Exclusive bonus features include Diagnosaurus DDx, 200 pediatrics topics, and medical news feeds. Explore these free sample topics:
-- The first section of this topic is shown below --
Basics
Description
An acquired, self-limited suppression of red cell production in an otherwise healthy child
Epidemiology
- Mean age at diagnosis is 26 months.
- <10% are >3 years of age at diagnosis.
- Slight male predominance (male/female 5.1:3.1)
- No seasonal predominance
Risk Factors
Genetics
- There is no simple genetic pattern.
- Familial transient erythroblastopenia of childhood has been reported (rarely), suggesting a combination of environmental factors and genetic propensity.
General Prevention
There is no known way to prevent transient erythroblastopenia of childhood.
Etiology
- Unknown
- Possible viral causes include parvovirus B19 and human herpesvirus 6 (HHV-6), but this remains hypothetical.
- A serum inhibitor, such as an IgG directed at the committed erythroid stem cell progenitor, has also been proposed but not yet proven.
-- To view the remaining sections of this topic, please log in or purchase a subscription --
Basics
Description
An acquired, self-limited suppression of red cell production in an otherwise healthy child
Epidemiology
- Mean age at diagnosis is 26 months.
- <10% are >3 years of age at diagnosis.
- Slight male predominance (male/female 5.1:3.1)
- No seasonal predominance
Risk Factors
Genetics
- There is no simple genetic pattern.
- Familial transient erythroblastopenia of childhood has been reported (rarely), suggesting a combination of environmental factors and genetic propensity.
General Prevention
There is no known way to prevent transient erythroblastopenia of childhood.
Etiology
- Unknown
- Possible viral causes include parvovirus B19 and human herpesvirus 6 (HHV-6), but this remains hypothetical.
- A serum inhibitor, such as an IgG directed at the committed erythroid stem cell progenitor, has also been proposed but not yet proven.
There's more to see -- the rest of this entry is available only to subscribers.